Recent BRCAPRO upgrades significantly improve calibration

Cancer Epidemiology Biomarkers and Prevention

Volumn 23, Issue 8, 2014, Pages 1689-1695

  Mazzola, Emanuele ^a   Chipman, Jonathan ^a   Cheng, Su Chun ^a   Parmigiani, Giovanni ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ACCURACY; ADULT; ARTICLE; BREAST CANCER; CALIBRATION; CANCER RISK; CANCER SURVIVAL; CONTRALATERAL BREAST CANCER; COUNSELING; ETHNICITY; FAMILY; FEMALE; GENE FREQUENCY; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; MODEL; PEDIGREE; PENETRANCE; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; VALIDATION STUDY; BIOLOGICAL MODEL; BREAST TUMOR; GENETIC PREDISPOSITION; GENETICS; HETEROZYGOTE; SECOND CANCER; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; CALIBRATION; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HUMANS; MODELS, GENETIC; NEOPLASMS, SECOND PRIMARY; PEDIGREE; PENETRANCE;

EID: 84905485368     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-13-1364     Document Type: Article

References (24)

1. American Cancer Society. Cancer facts and figures 2013. Available from: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/ document/acspc-036845.pdf.
2. National Cancer Institute. Genetics of breast and ovarian cancer (PDQ), 2013. Available from: http://www.cancer.gov/cancertopics/pdq/genetics/breast- and-ovarian/HealthProfessional/page2.
3. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72:1117-30.
4. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007;25:1329-33.
5. Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, et al. SEER Cancer Statistics Review, 1975-2010, based on November 2012 SEER data submission, posted to the SEER web site. Bethesda, MD: National Cancer Institute; 2013. Available from: http://seer.cancer.gov/csr/1975-2010/.
6. Parmigiani G, Chen S, Iversen ES Jr, Friebel TM, Finkelstein DM, Anton-Culver H, et al. Validity of models for predicting BRCA1 and BRCA2 mutations. Ann Intern Med 2007;147:441-50.
7. Katki HA. Incorporating medical interventions into carrier probability estimation for genetic counseling, BMC Med Genet 2007;8:13.
8. Tai YC, Domchek S, Parmigiani G, Chen S. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2007;99:1811-4.
9. Tai YC, Chen S, Parmigiani G, Klein AP. Incorporating tumor immunohistochemical markers in BRCA1 and BRCA2 carrier prediction. Breast Cancer Res 2008;10:401.
10. Chen S, Blackford A, Parmigiani G. Tailoring BRCAPRO to Asian-Americans. J Clin Oncol 2009;27:642-3.
11. Biswas S, Tankhiwale N, Blackford A, Barrera AM, Ready K, Lu K, et al. Assessing the added value of breast tumor markers in genetic risk prediction model BRCAPRO. Breast Cancer Res Treat 2012 May;133:347-55.
12. CaGene. Available from: http://www4.utsouthwestern.edu/breasthealth/ cagene/.
13. HughesRiskApps. Available from: http://www.hughesriskapps.com.
14. Ozanne EM, Loberg A, Hughes S, Lawrence C, Drohan B, Semine A, et al. Identification and management of women at high risk for hereditary breast/ovarian cancer syndrome. Breast J 2009;15:155-62.
15. Chipman J, Drohan B, Blackford A, Parmigiani G, Hughes K, Bosinoff P. Providing access to risk prediction tools via the HL7 XML-formatted risk web service. Breast Cancer Res Treat 2013;140:187-93.
16. Chen S, Wang W, Broman KW, Katki HA, Parmigiani G. BayesMendel: and R environment for Mendelian risk prediction. Stat Appl Genet Mol Biol 2004;3:Article 21.
17. Ready KJ, Vogel KJ, Atchley DP, Broglio KR, Solomon KK, Amos C. Accuracy of the BRCAPRO model among women with bilateral breast cancer. Cancer 2009;115:725-30.
18. Chen Y, Thompson W, Semenciw R, Mao Y. Epidemiology of contralateral breast cancer. Cancer Epidemiol Biomarkers Prev 1999;8:855-61.
19. Metcalfe K, Gershman S, Ghadirian P, Lynch HT, Snyder C, Tung N, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2004;15:2328-35.
20. Rubino C, Arriagada R, Delaloge S, Lê MG. Relation of risk of contralateral breast cancer to the interval since the first primary tumour. Br J Cancer 2010;102:213-9.
21. Graeser MK, Engel C, Rhiem K, Gadzicki D, Bick U, Kast K, et al. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2009;27:5887-92.
22. Pencina MJ, D'Agostino RB, Pencina KM, Janssens A C JW, Greenland P. Interpreting incremental value of markers added to risk prediction models. Am J Epidemiol 2012;176:473-81.
23. Kerr KF, Bansal A, Pepe M. Further insight into the incremental value of new markers: the interpretation of performance measures and the importance of clinical context. Am J Epidemiol 2012;176:482-7.
24. Sing T, Sander O, Beerenwinkel N, Lengauer T. ROCR: visualizing classifier performance in R. Bioinformatics 2005;21:3940-1.